Shanmugam R - Search Results

1

A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67.

Hahn NM, Zon RT, Yu M, Ademuyiwa FO, Jones T, Dugan W, Whalen C, Shanmugam R, Skaar T, Sweeney CJ. Hahn NM, et al. Among authors: shanmugam r. Ann Oncol. 2009 Dec;20(12):1971-6. doi: 10.1093/annonc/mdp244. Epub 2009 Jul 15. Ann Oncol. 2009. PMID: 19605506 Free article. Clinical Trial.

2

Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model.

Shanmugam R, Jayaprakasan V, Gokmen-Polar Y, Kelich S, Miller KD, Yip-Schneider M, Cheng L, Bhat-Nakshatri P, Sledge GW Jr, Nakshatri H, Zheng QH, Miller MA, DeGrado T, Hutchins GD, Sweeney CJ. Shanmugam R, et al. Prostate. 2006 Oct 1;66(14):1498-511. doi: 10.1002/pros.20482. Prostate. 2006. PMID: 16921510

3

A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species.

Shanmugam R, Kusumanchi P, Cheng L, Crooks P, Neelakantan S, Matthews W, Nakshatri H, Sweeney CJ. Shanmugam R, et al. Prostate. 2010 Jul 1;70(10):1074-86. doi: 10.1002/pros.21141. Prostate. 2010. PMID: 20209491

4

Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate.

Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H, Cheng L. Sweeney C, et al. Among authors: shanmugam r. Clin Cancer Res. 2004 Aug 15;10(16):5501-7. doi: 10.1158/1078-0432.CCR-0571-03. Clin Cancer Res. 2004. PMID: 15328189

5

A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen species.

Shanmugam R, Kusumanchi P, Appaiah H, Cheng L, Crooks P, Neelakantan S, Peat T, Klaunig J, Matthews W, Nakshatri H, Sweeney CJ. Shanmugam R, et al. Int J Cancer. 2011 May 15;128(10):2481-94. doi: 10.1002/ijc.25587. Int J Cancer. 2011. PMID: 20669221 Free PMC article.

6

Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies.

Holcomb B, Yip-Schneider MT, Matos JM, Dixon J, Kennard J, Mahomed J, Shanmugam R, Sebolt-Leopold J, Schmidt CM. Holcomb B, et al. Among authors: shanmugam r. J Gastrointest Surg. 2008 Feb;12(2):288-96. doi: 10.1007/s11605-007-0406-6. Epub 2007 Nov 30. J Gastrointest Surg. 2008. PMID: 18049840

7

Antimyeloma effects of a sesquiterpene lactone parthenolide.

Suvannasankha A, Crean CD, Shanmugam R, Farag SS, Abonour R, Boswell HS, Nakshatri H. Suvannasankha A, et al. Among authors: shanmugam r. Clin Cancer Res. 2008 Mar 15;14(6):1814-22. doi: 10.1158/1078-0432.CCR-07-1359. Clin Cancer Res. 2008. PMID: 18347184

8

A noncanonical Flt3ITD/NF-κB signaling pathway represses DAPK1 in acute myeloid leukemia.

Shanmugam R, Gade P, Wilson-Weekes A, Sayar H, Suvannasankha A, Goswami C, Li L, Gupta S, Cardoso AA, Baghdadi TA, Sargent KJ, Cripe LD, Kalvakolanu DV, Boswell HS. Shanmugam R, et al. Clin Cancer Res. 2012 Jan 15;18(2):360-369. doi: 10.1158/1078-0432.CCR-10-3022. Epub 2011 Nov 17. Clin Cancer Res. 2012. PMID: 22096027 Free PMC article.

9

Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML.

Sayar H, Liu Y, Gao R, Zaid MA, Cripe LD, Weisenbach J, Sargent KJ, Nassiri M, Li L, Konig H, Suvannasankha A, Pan F, Shanmugam R, Goswami C, Kapur R, Xu M, Boswell HS. Sayar H, et al. Among authors: shanmugam r. Oncotarget. 2017 Dec 25;9(5):5703-5715. doi: 10.18632/oncotarget.23655. eCollection 2018 Jan 19. Oncotarget. 2017. PMID: 29464028 Free PMC article.

10

De novo heterozygous Hb G-Waimanalo (α64(E13)Asp>Asn, CTG>CCG; HBA1:c.193G>A) variant in a sickle cell disease patient of an Indian tribe.

Kumar R, Mishra S, Uikey RS, Gwal A, Mun A, Bharti PK, Shanmugam R. Kumar R, et al. Among authors: shanmugam r. J Clin Pathol. 2021 May;74(5):336-338. doi: 10.1136/jclinpath-2020-206589. Epub 2020 Aug 19. J Clin Pathol. 2021. PMID: 32817264 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

275 results

Search Page

Filters